Last10K.com

La Jolla Pharmaceutical Co (LJPC) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

La Jolla Pharmaceutical Co

CIK: 920465 Ticker: LJPC
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Feb. 08, 2021
Jun. 30, 2020
Cover [Abstract]   
Document Type10-K  
Document Annual Reporttrue  
Document Transition Reportfalse  
Document Period End DateDec. 31, 2020  
Document Fiscal Year Focus2020  
Document Fiscal Period FocusFY  
Current Fiscal Year End Date--12-31  
Entity File Number1-36282  
Entity Registrant NameLA JOLLA PHARMACEUTICAL COMPANY  
Entity Incorporation, State or Country CodeCA  
Entity Tax Identification Number33-0361285  
Entity Address, Address Line One201 Jones Road  
Entity Address, Address Line TwoSuite 400  
Entity Address, City or TownWaltham  
Entity Address, State or ProvinceMA  
Entity Address, Postal Zip Code02451  
City Area Code617  
Local Phone Number715-3600  
Title of 12(b) SecurityCommon Stock, par value $0.0001 per share  
Trading SymbolLJPC  
Security Exchange NameNASDAQ  
Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Shell Companyfalse  
Entity Common Stock, Shares Outstanding 27,428,407 
Entity Central Index Key0000920465  
Amendment Flagfalse  
Entity Public Float  $ 78.0
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
ICFR Auditor Attestation Flagfalse  
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for its 2021 Annual Meeting of Shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.

  

View differences made from one year to another to evaluate La Jolla Pharmaceutical Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by La Jolla Pharmaceutical Co.

Continue

Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
M & A
Financial
Other
Filter by Subcategory:
All
Geography
Expense
Cash Flow
Product
Income
Other
Inside La Jolla Pharmaceutical Co's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Parenthetical)
Consolidated Balance Sheets
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Shareholders' Deficit
Acquisition Of Tetraphase Pharmaceuticals, Inc
Acquisition Of Tetraphase Pharmaceuticals, Inc (Tables)
Acquisition Of Tetraphase Pharmaceuticals, Inc - Summary Of Purchase Price Allocation As Of Acquisition Date (Details)
Acquisition Of Tetraphase Pharmaceuticals, Inc. Additional Information (Details)
Balance Sheet Details
Balance Sheet Details (Tables)
Balance Sheet Details - Additional Information (Details)
Balance Sheet Details - Property Plant And Equipment (Details)
Balance Sheet Details - Schedule Of Intangible Assets, Net (Details)
Balance Sheet Details - Schedule Of Inventory (Details)
Balance Sheet Details - Schedule Of Other Noncurrent Liabilities (Details)
Balance Sheet Details - Schedule Of Prepaid Expenses And Other Current Assets (Details)
Balance Sheet Details - Summary Of Accrued Expenses (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies - Additional Information (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Schedule Of Concentration Risk (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)
Company-Wide Realignments
Company-Wide Realignments - Additional Information (Details)
Deferred Royalty Obligation
Deferred Royalty Obligation - Additional Information (Details)
Defined Contribution Plan
Defined Contribution Plan - Additional Information (Details)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies - Additional Information (Details)
Equity Incentive Plans
Equity Incentive Plans (Tables)
Equity Incentive Plans - Share-Based Compensation Expense (Details)
Equity Incentive Plans - Stock Option Activity (Details)
Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)
Equity Incentive Plans - Stock Options, Valuation Assumptions (Details)
Equity Incentive Plans- Narrative (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Provision For Income Taxes (Details)
Income Taxes - Schedule Of Significant Components Deferred Tax Assets (Details)
License Agreements
License Agreements - Additional Information (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Other Income-Related Party - Additional Information (Details)
Other Income???Related Party
Shareholders Deficit (Details)
Shareholders Equity
Subsequent Event
Subsequent Events - Additional Information (Details)
Ticker: LJPC
CIK: 920465
Form Type: 10-K Annual Report
Accession Number: 0001564590-21-011366
Submitted to the SEC: Mon Mar 08 2021 8:30:48 AM EST
Accepted by the SEC: Mon Mar 08 2021
Period: Thursday, December 31, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ljpc/0001564590-21-011366.htm